Publicacións en colaboración con investigadores/as de Hospital Vall d'Hebron (20)

2024

  1. National Survey and consensus document on dosing strategies for beta-lactam antibiotics against multidrug-resistant gram-negative bacilli (MDR-GNB) in critically ill patients undergoing extracorporeal life support techniques: The DOSEBL study protocol

    Farmacia Hospitalaria

  2. Pharmacokinetics of eculizumab in adult and pediatric patients with atypical hemolytic uremic syndrome and C3 glomerulopathy

    Farmacia Hospitalaria, Vol. 48, Núm. 1, pp. 16-22

  3. Preclinical characterization of endotoxin-induced uveitis models using OCT, PET/CT and proteomics

    International Journal of Pharmaceutics, Vol. 662

  4. Prioritization of initiatives 2024–2027 of the strategic map of pharmaceutical outpatient care of the Spanish Society of Hospital Pharmacy

    Farmacia Hospitalaria

2023

  1. A Randomized Trial of Dolutegravir Plus Darunavir/ Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes

    Open Forum Infectious Diseases, Vol. 10, Núm. 11

  2. Disease-modifying treatments for patients with multiple sclerosis in Spain

    Farmacia Hospitalaria, Vol. 47, Núm. 4, pp. 155-160

  3. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study

    Frontiers in Cellular and Infection Microbiology, Vol. 13

  4. [Translated Article] Disease-modifying treatments for patients with multiple sclerosis in Spain

    Farmacia Hospitalaria, Vol. 47, Núm. 4, pp. T155-T160

2020

  1. La farmacotecnia hospitalaria frente a la COVID-19

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 44, Núm. 7, pp. 49-52

  2. Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 12, pp. 3517-3524

2019

  1. An Observational Study of the Efficacy and Safety of Voriconazole in a Real-Life Clinical Setting

    Journal of Chemotherapy, Vol. 31, Núm. 1, pp. 49-57

  2. Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis

    Oncologist, Vol. 24, Núm. 8, pp. e687-e695

2017

  1. Pharmacotherapy follow-up of patients under treatment with biologic agents for chronic inflammatory systemic conditions: An agreement among hospital pharmacists for the standardized collection of a minimum set of data

    Farmacia Hospitalaria, Vol. 41, Núm. 1, pp. 31-48

2016

  1. Change of concept about the regulation of angiotensin II-induced monocyte chemoattractant protein-1 production in human endothelial cells

    Vascular Pharmacology, Vol. 80, pp. 20-34

  2. Consumption of systemic antifungal agents among acute care hospitals in Catalonia (Spain), 2008-2013

    Expert Review of Anti-Infective Therapy, Vol. 14, Núm. 1, pp. 137-144

2015

  1. Advanced glycation end-products as long-term predictors of death and reinfarction after an acute coronary syndrome

    Biomarkers in Medicine, Vol. 9, Núm. 3, pp. 209-216

  2. Key structural and functional differences between early and advanced glycation products

    Journal of Molecular Endocrinology, Vol. 56, Núm. 1, pp. 23-37

2014

  1. Algoritmo de diagnóstico y tratamiento del angioedema hereditario como herramienta para su manejo (Farmacia Hospitalaria (2013) 37, 6 (521-529))

    Farmacia Hospitalaria

2013

  1. Treatment adherence and unmet needs at hospital pharmacy for the care of Spanish patients with multiple sclerosis

    European Journal of Hospital Pharmacy, Vol. 20, Núm. 1, pp. 20-25

2011

  1. Utilización de dexrazoxano como antidoto para el tratamiento de la extravasación de antraciclinas en población pediátrica

    Atencion Farmaceutica, Vol. 13, Núm. 5, pp. 303-305